Short Answer

The model assigns meaningfully higher odds than the market for Medtronic's cardiovascular organic growth in Q1 to be Above 6% (24.7% model vs 0.0% market). This is driven by Medtronic's Q1 FY2027 overall organic revenue growth guidance of 11.5% to 12.0%, significantly boosted by an extra selling week, and the Cardiovascular segment's consistent historical outperformance.

1. Market Behavior & Drivers

This market's price action displays a dramatic, near-vertical increase over a two-day period. The implied probability of Medtronic's Q1 FY2027 cardiovascular organic growth meeting the market's criteria moved from a low of 1.0% on August 7, 2026, to 94.0% by August 9, 2026. This represents an almost complete reversal in outlook. The provided context, however, offers no clear catalyst for this extreme price movement, as it primarily notes that the relevant financial data has not yet been released.
The most critical feature of this market is the complete absence of trading volume. With zero contracts traded, the price changes reflect shifts in unfilled bids and asks, not executed transactions. This indicates a highly illiquid market with no active participation or capital commitment behind the price levels shown. The lack of volume means traditional technical indicators like support and resistance levels are not meaningful.
The chart's price trajectory suggests a rapid shift in sentiment from overwhelmingly negative to highly positive. However, this reading is superficial. Given the zero-volume environment, the price cannot be interpreted as a reliable consensus forecast. It likely reflects the actions of a single participant setting an initial low offer and then a subsequent high bid, without any counter-party engaging to establish a traded price. The market is effectively unformed.
  • Medtronic's Q1 FY2027 cardiovascular growth above 6% is likely, given 11.5-12.0% overall guidance.
  • The segment historically outperforms company growth, further boosted by an extra Q1 selling week.
  • Strong product drivers like Cardiac Ablation Solutions are expected to support robust performance.

Current Context

Medtronic's Q1 FY2027 cardiovascular growth is not yet reported. As of August 9, 2026, Medtronic has not released its Q1 FY2027 financial results; consequently, the cardiovascular organic revenue growth figure for this period is unavailable [1][2][3][4][5][6]. The company is scheduled to report its Q1 FY2027 results on Tuesday, September 1, 2026, at 5:45 a.m. Central Time, with a webcast following at 6:45 a.m. Central Time [7][8]. The first fiscal quarter concluded on Friday, July 31, 2026 [7].
Overall Q1 FY2027 organic growth guidance is available, not cardiovascular. Medtronic's FY2027 organic revenue growth guidance includes an approximate 11.5% to 12.0% organic growth for the first quarter overall, as stated in FY2026 Q4 materials [9][10]. However, the company has not explicitly provided a separate Q1 FY2027 cardiovascular organic revenue growth figure [9]. For historical context, the most recently reported cardiovascular organic growth was 7.00% in Q1 FY2026 [1][2][3][4][5][6]. Medtronic's cardiovascular segment delivered 10.10% organic growth in Q4 FY2026, driven by factors such as CAS growth and the expanded CE Mark for Affera/Sphere-9 in ventricular arrhythmias [9][10][1][2][3][4][5][6]. An external market is available for "Above 9% cardiovascular organic revenue growth in Q1 2027", but this is not an official company KPI [11].
Sources (11)
  1. 1www.fool.comOctagon Agentfool.com
  2. 2www.etftrends.comOctagon Agentetftrends.com
  3. 3www.defenseworld.netOctagon Agentdefenseworld.net
  4. 4www.prnewswire.comOctagon Agentprnewswire.com
  5. 5www.fool.comOctagon Agentfool.com
  6. 6www.fool.comOctagon Agentfool.com
  7. 7Medtronic to announce financial results for its first quarter of fiscal...news.medtronic.com
  8. 8Investor Relations | Medtronic - Overviewinvestorrelations.medtronic.com
  9. 9Q4 FY26filecache.investorroom.com
  10. 10Medtronic (MDT) Q4 2026 Earnings Call Transcript & Audiostockanalysis.com
  11. 11Medtronic cardiovascular organic growth in Q1 - Kalshikalshi.com

2. Price Chart

Historical Price (Probability)

Outcome probability
Date

3. Market Data

Contract Snapshot

For a given percentage threshold, a YES resolution occurs if Medtronic's cardiovascular organic growth in Q1 is strictly above that specified percentage. A NO resolution occurs if the growth is at or below the specified percentage. The market closes for trading on September 1, 4:00 PM EDT, with a maximum payout date of December 29, 2026. The provided content does not detail specific data sources or additional settlement conditions.

Market Discussion

Medtronic's cardiovascular organic growth was 7.0% in Q1 FY2026, significantly boosted by nearly 50% revenue growth in its Cardiac Ablation Solutions (CAS) segment, largely attributed to pulsed field ablation products [1][2][3]. For Q1 FY2027, the company has announced guidance for approximately 11.5% to 12% organic growth, a projection analysts support, citing continued CAS momentum and strategic investments made in June 2026 [3][4][5]. Current market odds suggest a 70% chance of growth exceeding 8% [6].

Sources (6)
  1. 1medtronic.comnews.medtronic.com
  2. 2tokenist.com
  3. 3alpha-sense.com
  4. 4mddionline.com
  5. 5prnewswire.com
  6. 6kalshi.com

4. Trader Dashboard

This scorecard was computed Aug 9, 2026 and may not reflect current market conditions.

Trust profile
Event quality1
Poor
Liquidity
1

7 contracts · worst first

Above 12%1
Very thin · low confidence

Light recent trading — size may not fill near the screen price.

Above 6%—
No recent trading to measure

No recent trading to measure

Above 7%—
No price to anchor on

No price to anchor on

Above 8%—
No price to anchor on

No price to anchor on

Above 9%—
No price to anchor on

No price to anchor on

Above 10%—
No price to anchor on

No price to anchor on

Above 11%—
No price to anchor on

No price to anchor on

Move quality
—

No reading right now

7 contracts · worst first

Above 12%—
No significant move

No significant move: |move| 1.84 log-odds, 5.0c, vol 1

Above 6%—
No significant move

No significant move: |move| 7.35 log-odds, 93.0c, vol 0

Above 7%—
Only 0 candle closes

Only 0 candle closes

Above 8%—
Only 0 candle closes

Only 0 candle closes

Above 9%—
Only 0 candle closes

Only 0 candle closes

Above 10%—
Only 0 candle closes

Only 0 candle closes

Above 11%—
Only 0 candle closes

Only 0 candle closes

Rule clarity
—Clear

Rules read clean and objective

7 contracts · worst first

Above 12%100
Clear · high confidence

All checks pass

objective outcome · Clearofficial source · Cleartime boundary · Clear
Above 6%100
Clear · high confidence

All checks pass

objective outcome · Clearofficial source · Cleartime boundary · Clear
Above 7%100
Clear · high confidence

All checks pass

objective outcome · Clearofficial source · Cleartime boundary · Clear
Above 8%100
Clear · high confidence

All checks pass

objective outcome · Clearofficial source · Cleartime boundary · Clear
Above 9%100
Clear · high confidence

All checks pass

objective outcome · Clearofficial source · Cleartime boundary · Clear
Above 10%100
Clear · high confidence

All checks pass

objective outcome · Clearofficial source · Cleartime boundary · Clear
Above 11%100
Clear · high confidence

All checks pass

objective outcome · Clearofficial source · Cleartime boundary · Clear

trader_dashboard_lean_v1.13 · computed Aug 9, 2026

5. How did Medtronic's cardiovascular growth in the most recent reported quarter compare to that of its key competitors, Boston Scientific and Abbott Laboratories?

Medtronic Cardiovascular Growth10.1% organic revenue growth (Q4 FY26) [1][2][3][4][5]
Boston Scientific Cardiovascular Growth7.8% organic revenue growth (Q2 2026) [6][7][8][9][10]
Abbott Medical Devices Growth8.4% comparable sales growth (Q2 2026) [11][12][13][14]
Medtronic's cardiovascular growth exceeded Boston Scientific's in recent quarters. Medtronic's cardiovascular portfolio achieved 10.1% organic revenue growth in its most recent reported quarter, Q4 fiscal year 2026, which concluded on April 24, 2026 [1][2][3][4][5]. This performance outpaced Boston Scientific's cardiovascular segment, which reported 7.8% organic revenue growth in its most recent reported quarter, Q2 2026, ending June 30, 2026 [6][7][8][9][10]. Medtronic's Q1 fiscal year 2027 cardiovascular organic revenue growth is not yet reported as of August 9, 2026, though the company anticipates reaching $2 billion in trailing revenue during that quarter [1][2][5].
Comparing Abbott's diverse cardiovascular segments directly is challenging. Abbott Laboratories does not report a consolidated 'Cardiovascular' revenue growth figure [11][12][13][14]. Instead, Abbott reports growth for individual medical device businesses. For example, Electrophysiology saw 13.4% comparable sales growth, and Rhythm Management grew 9.5% in Q2 2026. Abbott's broader Medical Devices segment collectively grew 8.4% on a comparable basis during its most recent reported quarter, Q2 2026 [11][12][13][14].
Sources (14)
  1. 1Medtronic reports fourth quarter and full year fiscal 2026 resultsnews.medtronic.com
  2. 2Q4 FY26filecache.investorroom.com
  3. 3Documentsec.gov
  4. 4Exhibit 99.1 - FY26 Q4 Earnings Releasemma.prnewswire.com
  5. 5Medtronic (MDT) Q4 2026 Earnings Call Transcript & Audiostockanalysis.com
  6. 6Boston Scientific announces results for second quarter 2026news.bostonscientific.com
  7. 7Q2 2026 Financial & Operational Highlightsinvestors.bostonscientific.com
  8. 8Documentsec.gov
  9. 9Interested in our Q2 2026 earnings? - Boston Scientificnews.bostonscientific.com
  10. 10Boston Scientific (BSX) Q2 2026 Earnings Call Transcript | The Motley Foolfool.com
  11. 11Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance - Jul 16, 2026abbott.mediaroom.com
  12. 12Documentsec.gov
  13. 13Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidanceprnewswire.com
  14. 14[PDF] Abbott Reports Second-Quarter 2026 Results and Raises Full-Year...abbottinvestor.com

6. How has Medtronic's Cardiovascular segment growth historically performed relative to the company's overall organic growth guidance for the same quarter?

Cardiovascular Segment Organic Growth (Q4 FY26)10.1% [1][2][3]
Overall Company Organic Growth (Q4 FY26)6.6% [1][2][3]
Full-Year FY27 Organic Revenue Growth Guidance6.75% to 7.25% [1][2][3]
Medtronic's Cardiovascular segment consistently outperforms overall company organic revenue growth. In recent quarters, the Cardiovascular segment has shown stronger organic revenue growth compared to the company's overall performance [1][2][3]. For instance, in Q4 FY26, the Cardiovascular segment achieved 10.1% organic growth, significantly surpassing the company's overall organic revenue growth of 6.6% during the same period [1][2][3].
Quarterly organic growth guidance for past periods remains unspecified. While the Cardiovascular segment demonstrates a strong recent track record, specific details regarding its historical growth performance relative to Medtronic's overall organic growth guidance for any given quarter are not available [1][2][3]. Medtronic has issued full-year FY27 organic revenue growth guidance of 6.75% to 7.25%, which accounts for a 53rd week and the full-year consolidation of the Diabetes business. However, the provided information does not include the company's overall organic growth guidance for past quarters, such as Q4 FY26, or for the upcoming Q1 FY2027 [1][2][3].
Sources (3)
  1. 1Medtronic reports fourth quarter and full year fiscal 2026 resultsnews.medtronic.com
  2. 2Documentsec.gov
  3. 3Medtronic reports fourth quarter and full year fiscalfilecache.investorroom.com

7. Which specific product lines or recent regulatory approvals within Medtronic's cardiovascular portfolio are expected to be the primary growth drivers in Q1 FY2027?

CAS global revenue growth Q4 FY202678% [1][2][3]
CAS annualized revenue target Q1 FY2027over $2 billion [1][2][3]
Medtronic Q1 FY2027 organic revenue growth guidanceapproximately 11.5% to 12.0% [1][4][5][6]
Medtronic’s cardiovascular portfolio anticipates significant growth in Q1 FY2027. Primary growth drivers are expected from Cardiac Ablation Solutions (CAS), especially the Affera Mapping and Ablation System, which includes the Sphere-9 catheter [1][2][3][7]. Further momentum is anticipated from Micra leadless pacemakers, the OmniaSecure defibrillation lead, and the Symplicity renal denervation system [1][2][3][7]. Recent regulatory approvals for the Affera system and the OmniaSecure lead are also key contributors to this expected growth [8][9].
Cardiac Ablation Solutions are a major revenue growth engine. This segment delivered 78% global revenue growth in Q4 FY2026, with the company aiming to annualize over $2 billion in revenue in Q1 FY2027 [1][2][3]. A significant regulatory milestone supporting this growth is the expanded CE Mark for the Affera Mapping and Ablation System (Sphere-9) for ventricular arrhythmias, which was announced in August 2026 [8]. The OmniaSecure defibrillation lead also contributes significantly, having received FDA approval for its conduction system pacing indication in March 2026, making it the first lead of its kind [9].
Other product lines and approvals bolster overall growth projections. Micra leadless pacemakers are expected to provide continued momentum [1][2][3][7]. Additionally, the Mosaic Neo mitral bioprosthesis, which received FDA approval in April 2026, has seen rapid adoption across major US hospitals [10]. Medtronic has guided to Q1 FY2027 organic revenue growth of approximately 11.5% to 12.0% for the company as a whole, with the Cardiovascular portfolio anticipated to maintain strong performance [1][4][5][6].
Sources (10)
  1. 1Q4 FY26filecache.investorroom.com
  2. 2Medtronic (MDT) Q4 2026 Earnings Call Transcript & Audiostockanalysis.com
  3. 3Medtronic (MDT) Q4 2026 Earnings Transcript - AOLaol.com
  4. 4Medtronic reports fourth quarter and full year fiscal 2026 results; delivers highest annual revenue growth in 10 years - Jun 3, 2026news.medtronic.com
  5. 5Documentsec.gov
  6. 6Medtronic reports fourth quarter and full year fiscalfilecache.investorroom.com
  7. 7Medtronic boosts revenue by nearly double digits in Q4 | MedTech Divemedtechdive.com
  8. 8Medtronic announces expanded CE Mark indication for Affera™ Mapping and Ablation System and Sphere-9™ Catheter for treatment of ventricular arrhythmias - Aug 6, 2026news.medtronic.com
  9. 9Medtronic OmniaSecure™ defibrillation lead is the first lead of its kind to receive FDA approval for conduction system pacing - Mar 23, 2026news.medtronic.com
  10. 10New Medtronic Mosaic Neo™ mitral bioprosthesis sees rapid adoption with successful implants across major US hospitals following FDA approvalnews.medtronic.com

8. What has been the historical trend of Medtronic's quarterly cardiovascular organic revenue growth from fiscal year 2024 through fiscal year 2026?

FY2024 Cardiovascular Organic Revenue Growth5.0% [1][2]
FY2025 Cardiovascular Organic Revenue Growth6.3% [3][4][5][6]
FY2026 Cardiovascular Organic Revenue Growth9.3% [7]
Medtronic's cardiovascular organic revenue growth showed an upward trend from FY2024 to FY2026. While quarterly growth rates varied across this period, the full year performance consistently improved. In fiscal year 2024, the full year organic revenue growth for Medtronic's Cardiovascular segment reached 5.0%, with specific quarterly growth rates including 6.2% in Q1 and 4.0% in Q4 [1][2].
Full-year growth rates significantly improved through fiscal years 2025 and 2026. Fiscal year 2025 saw the full year growth rate increase to 6.3%, supported by quarterly performances such as 7.0% in Q1 and 7.8% in Q4 [3][4][5][6]. This upward trend continued into fiscal year 2026, where the full year Cardiovascular organic revenue growth accelerated significantly to 9.3% [7]. This period featured strong quarterly growth, with Q1 at 7.0%, Q2 at 7.1%, Q3 reaching 10.6%, and Q4 at 10.1% [7][8][9][10].
Sources (10)
  1. 1Medtronic reports full year and fourth quarter fiscal 2024 financial results; announces dividend increase - May 23, 2024news.medtronic.com
  2. 2Exhibit 99.1 - FY24 Q1 Earnings Releasemma.prnewswire.com
  3. 3Exhibit 99.1 - FY25 Q2 Earnings Releasemma.prnewswire.com
  4. 4Documentsec.gov
  5. 5Medtronic Reports Strong Q2 FY2025 Financial Results and Raises Full-Year Guidance-VCBeatvcbeathealth.com
  6. 6Medtronic reports second quarter fiscal 2025 financial resultsfilecache.investorroom.com
  7. 7Medtronic reports fourth quarter and full year fiscal 2026 results; delivers highest annual revenue growth in 10 years - Jun 3, 2026news.medtronic.com
  8. 8Medtronic reports strong third quarter fiscal 2026 results with highest enterprise revenue growth in 10 quarters - Feb 17, 2026news.medtronic.com
  9. 9Exhibit 99.1 - FY26 Q1 Earnings Releasemma.prnewswire.com
  10. 10Exhibit 99.1 - FY26 Q3 Earnings Releasemma.prnewswire.com

9. What macroeconomic or healthcare industry-wide factors, such as hospital procedure volumes or reimbursement changes, could materially impact Medtronic's cardiovascular sales during Q1 FY2027?

Foreign Exchange Tailwind (Q1 FY2027)neutral to $50 million [1][2][3][4]
Tariffs Impact$75 million (expected) [3][5][4]
Fuel/Transportation Costs Headwindapproximately 1% (expected) [3][5][4]
Macroeconomic factors will significantly influence Medtronic's Q1 FY2027 financial performance. Medtronic projects a foreign exchange tailwind ranging from neutral to $50 million for the quarter ending July 31, 2026. However, this positive impact is expected to be offset by an anticipated $75 million impact from tariffs and an approximate 1% headwind stemming from elevated fuel and transportation costs, primarily associated with the Middle East conflict. These macroeconomic elements are expected to materially affect Medtronic's overall financial results, including its cardiovascular sales [3][5][4][1][2].
Hospital challenges persist, yet Medtronic's cardiovascular portfolio shows strong growth. Within the healthcare industry, hospitals continue to manage significant workforce pressures and rising operational costs. Despite a 2.6% increase in Medicare 2026 OPPS/ASC payment rates, hospitals still face ongoing financial strain due to underpayments by government payers [6][7][8]. These industry-wide operational and reimbursement challenges could affect hospital procedure volumes, potentially impacting Medtronic's cardiovascular sales. Despite these industry headwinds, Medtronic's cardiovascular portfolio is experiencing growth driven by market share gains in Cardiac Rhythm Management and Cardiac Ablation Solutions (CAS), with the company on track to achieve $2 billion in annual CAS revenue by Q1 FY2027 [3][9][4].
Sources (9)
  1. 1Medtronic to announce financial results for its first quarter of fiscal...news.medtronic.com
  2. 2Medtronic posts FY26 results and FY27 guidance | MDT 8-K Filingstocktitan.net
  3. 3Q4 FY26filecache.investorroom.com
  4. 4https://finance.biggo.com/quote/MDT/earnings-call?t=US_MDT_2026-06-03finance.biggo.com
  5. 5Medtronic (MDT) Q4 2026 Earnings Call Transcript & Audiostockanalysis.com
  6. 6Costs of Caring | AHA - American Hospital Associationaha.org
  7. 7CMS Begins Investigation into Hospital Cost-to-Charge Ratios, Hospital Outlier Payments, and Charge Description Mastersmhanet.imgix.net
  8. 8SUMMARY - 2026 Medicare OPPS _ ASC Final Rules(69246404.1)aahks.org
  9. 9Medtronic (MDT) Cardiovascular Business Expands Amid Macro Woes | Nasdaqnasdaq.com

10. What Could Change the Odds

Key Catalysts

Medtronic is expected to report its Q1 fiscal 2027 financial results on Tuesday, September 1, 2026 [1][2]. The quarter ended on July 31, 2026 [1][2]. The company guided to enterprise organic revenue growth of approximately 11.5% to 12.0% for the first quarter of fiscal year 2027 [1][2].
Key growth drivers for the quarter include the Cardiac Ablation Solutions (CAS) business, which is on track to reach $2 billion in trailing revenue in Q1 FY27 [1][2][3]. Additionally, an extra selling week is projected to contribute 500-600 basis points to Q1 FY27 growth [1][2][3]. Conversely, potential headwinds include a $75 million impact from tariffs in Q1 and a foreign exchange impact ranging from neutral to a $50 million tailwind [1][3].
As of 2026-08-09, the Q1 FY2027 cardiovascular organic revenue growth figure is not yet available, pending the September 1 release [1][4][5][6][7][8]. The most recent reported cardiovascular performance was 10.1% organic revenue growth in Q4 FY2026 for the Cardiovascular Portfolio [2][4][5][6][7][8]. Prediction markets are tracking cardiovascular organic revenue growth thresholds, such as above 9%, for Q1 2027 [9]. Bullish catalysts include this recent cardiovascular momentum and the continued product expansion in electrophysiology, specifically the Affera/Sphere-9 indication expansion for ventricular arrhythmias [9][4][5][6][7][8].

Key Dates & Catalysts

  • Expiration: December 30, 2026
  • Closes: December 30, 2026
Sources (9)
  1. 1Q4 FY26filecache.investorroom.com
  2. 2Medtronic (MDT) Q4 2026 Earnings Call Transcript & Audiostockanalysis.com
  3. 3Medtronic boosts revenue by nearly double digits in Q4 | MedTech Divemedtechdive.com
  4. 4www.fool.comOctagon Agentfool.com
  5. 5www.etftrends.comOctagon Agentetftrends.com
  6. 6www.defenseworld.netOctagon Agentdefenseworld.net
  7. 7www.prnewswire.comOctagon Agentprnewswire.com
  8. 8www.fool.comOctagon Agentfool.com
  9. 9Medtronic cardiovascular organic growth in Q1 - Kalshikalshi.com

12. Related News

+64.0pp
Last updated: September 1, 2026, 12:39 UTC

Medtronic Earnings Beat Drives Cardiovascular Growth Bets to Near Certainty

Medtronic's first-quarter fiscal 2027 earnings report on Tuesday, September 1, 2026, which revealed robust 19.5% organic growth in its Cardiovascular Portfolio, triggered a significant repricing in a ...